1.00
+1.01%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bioporto A/S
Its shares trade on Nasdaq Copenhagen under the ticker BIOPOR.CO. It has been listed since 2 January 1985. In the fiscal year to 31 December 2025, it reported revenue of DKK 40.3m and a net loss of DKK 82.1m. At that date it held total assets of DKK 93.2m and shareholders' equity of DKK 63.0m.
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Jan 1985
- Employees
- 26
- Website
- bioporto.com ↗
Leadership
Pay as last reported
- Mr. Jens Due OlsenIndependent Chairman of the Board
- Mr. Carsten BuhlChief Executive Officer
- Mr. Peter Moerch EriksenGroup Chief Executive Officer, since 2013
- Mr. Henrik JuuelIndependent Vice Chairman of the Board, since 2024
- Mr. Niels NielsenChief Financial Officer, Executive Vice President
- Ms. Gry LarsenExecutive Vice President and Chief Legal Officer
- Mr. Christopher BirdChief Medical Officer
- Ms. Donna HaireDirector
- Mr. Mats ThorenIndependent Director
- Ms. Christina ThomsenInvestor Relations Manager
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Advanced technology and expertise in diagnostic tests.
- Strong market presence and brand reputation in the medical industry.
- Well-established distribution networks.
Weaknesses
- Dependence on a limited number of key clients for revenue.
- Relatively small size compared to some competitors.
- Limited product portfolio.
Opportunities
- Growing demand for diagnostic tests, especially in emerging markets.
- Expansion into new geographic regions.
- Introduction of new diagnostic products.
Threats
- Intense competition from larger and more established companies.
- Regulatory constraints and changing healthcare policies.
- Economic downturn impacting healthcare spending.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.